BI 2536 is primarily used in research settings as a potent and selective inhibitor of PLK1 (Polo-like kinase 1), a key enzyme involved in cell division. Its application is significant in studying the mechanisms of mitosis and the role of PLK1 in cancer cell proliferation. Researchers utilize BI 2536 to investigate its potential as a therapeutic agent in various cancers, as inhibiting PLK1 can disrupt tumor growth. Additionally, it serves as a valuable tool in preclinical studies to understand cell cycle regulation and to develop targeted cancer therapies. Its use has contributed to advancements in oncology research, particularly in identifying new strategies for cancer treatment.